Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27850219 | 0.81 | KDM4E (0.44) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL27813844 | 0.81 | LMNA (0.39) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL5125138 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL27995497 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL686891 | 0.78 | MAPT (0.33) | SMN1; SMN2ALDH1A1KDM4ETDP1LMNA | |
| SCHEMBL1135127 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL29159093 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL4269112 | 0.75 | CTSL (0.38) | SMN1; SMN2ALDH1A1HPGDF2GLA | |
| SCHEMBL27702056 | 0.75 | MALT1 (0.37) | SMN1; SMN2ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL1291212 | 0.74 | KDM4E (0.43) | ALDH1A1HPGDF2GLAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9968628-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-15 | — | — | US | disclosed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-1736478-B1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS INC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2319856-B1 | Methods and compositions for treating hepatitis c virus | IDENIX PHARMACEUTICALS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20130315863-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS | UNIVERSITA' DEGLI STUDI DI CAGLIARI (IT) | 2013-11-28 | — | — | US | disclosed |
| US-20130315862-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA' DEGLI STUDI DI CAGLIARI (IT) | 2013-11-28 | — | — | US | disclosed |
| US-7148206-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7138376-B2 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7105493-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7101861-B2 | Methods and compositions for treating flaviviruses and pestiviruses | INDENIX PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060166865-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX PHARMACEUTICALS INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1669364-A2 | Methods and compositions for treating hepatitis C virus | Idenix (Cayman) Limited (KY) | 2006-06-14 | — | — | EP | disclosed |
| US-6914054-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC | 2005-06-23 | — | — | US | disclosed |
| US-20050124532-A1 | Methods and compositions for treating hepatitis C virus | SOMMADOSSI JEAN-PIERRE (US) | 2005-06-09 | — | — | US | disclosed |
| US-6812219-B2 | A MODIFIED NUCLEOSIDE COMPRISING A PURINE OR PYRIMIDINE RING FOR TREATING VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2004-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | MTAP, PHOSPHO1, PNP | SMN1; SMN2 209/4885ALDH1A1 3300/4885HPGD 2320/4885 |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
| US-20130315862-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
| US-20060166865-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | MTAP, PHOSPHO1, PNP | SMN1; SMN2 209/4885ALDH1A1 3300/4885HPGD 2320/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
| US-20130315863-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS | MTAP, PNP, NSUN2 | SMN1; SMN2 163/4885ALDH1A1 2309/4885HPGD 2058/4885 |
| US-20050124532-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | SMN1; SMN2 2411/4885ALDH1A1 929/4885HPGD 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.